# DARWIN Study: A Randomization/Withdrawal Efficacy Study of Dexloxiglumide in Constipation-Predominant Irritable Bowel Syndrome (C-IBS)

> **NCT00220090** · PHASE3 · COMPLETED · sponsor: **Rottapharm**

## Conditions studied

- Irritable Bowel Syndrome

## Interventions

- **DRUG:** dexloxiglumide

## Key facts

- **NCT ID:** NCT00220090
- **Lead sponsor:** Rottapharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2006-09
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2008-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00220090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00220090, "DARWIN Study: A Randomization/Withdrawal Efficacy Study of Dexloxiglumide in Constipation-Predominant Irritable Bowel Syndrome (C-IBS)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00220090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*